Cargando…
High concordance of 70‐gene recurrence risk signature and 80‐gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early‐stage breast cancer
BACKGROUND AND OBJECTIVES: With increased neoadjuvant therapy recommendations for early‐stage breast cancer patients due to the COVID‐19 pandemic, it is imperative that molecular diagnostic assays provide reliable results from preoperative core needle biopsies (CNB). The study objective was to deter...
Autores principales: | Crozier, Jennifer A., Barone, Julie, Whitworth, Pat, Cheong, Abraham, Maganini, Robert, Tamayo, Jose Perez, Dauer, Patricia, Wang, Shiyu, Audeh, William, Glas, Annuska M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305900/ https://www.ncbi.nlm.nih.gov/pubmed/34964996 http://dx.doi.org/10.1002/jso.26780 |
Ejemplares similares
-
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
por: Whitworth, Pat, et al.
Publicado: (2022) -
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
por: Whitworth, Pat W., et al.
Publicado: (2022) -
A breast cancer gene signature for indolent disease
por: Delahaye, Leonie J. M. J., et al.
Publicado: (2017) -
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014) -
Pathology Examination of Breast Reduction Specimens: Dispelling the Myth
por: Fisher, Mark, et al.
Publicado: (2020)